EU Message: This test is not available to persons established in the EU.
Understand the Genetic Factors Influencing Mental Wellness
The DNA Signature – Mind & Mood panel offers insights into genetic factors associated with emotional regulation, cognitive longevity, stress resilience, and sleep architecture; providing insight into the biochemical drivers behind mood and cognitive health. The report translates complex genetic variants into a prioritized, actionable strategy. Empowering practitioners to design personalized neuro-nutritional, lifestyle, and brain-support protocols before functional imbalances progress.
What Patients Might Benefit from DNA Signature -Mind & Mood Testing?
Patients with the following symptoms or conditions may benefit from DNA Signature – Mind & Mood testing
Persistent Mood Imbalances & High Stress Reactivity
Aging Adults & Individuals Focused on Cognitive Health
Patients with Sleep Architecture Disruptions
Methylation & Neuro-Nutritional Bottlenecks
Details
Why Use the DNA Signature – Mind & Mood Profile?
The DNA Signature – Mind & Mood profile provides a comprehensive genomic analysis of neuro-chemical balance, cognitive longevity, stress resilience, and sleep architecture. By evaluating interconnected pathways across central nervous system function, cellular energetics, and neurotransmitter turnover, this panel equips practitioners with an objective blueprint to understand emotional regulation, cognitive trajectory, and restorative rest.
Core Functional Domains Evaluated
Emotional Regulation, Mood & Stress Resilience
Neuro-Behavioral Tendencies: Maps genetic risk profiles and predispositions associated with anxiety, depression, rumination, and OCD behaviors.
GABA & Excitatory Balance: Assesses GAD1 activity to evaluate the conversion of glutamate to GABA, clarifying central nervous system inhibitory tone and anxiety vulnerability.
Stress Response Architecture: Identifies individual Stress Phenotypes and biological Stress Adaptation capacity to explain distinct thresholds for psychological and physiological stress.
Executive Function & Memory: Evaluates genetic markers governing general cognition, memory, attention, and structural white matter integrity.
Neuro-Degenerative Trajectory: Maps baseline risk factors for MCI (Mild Cognitive Impairment), Parkinson’s Disease, and Alzheimer’s Disease (APOE Status) to guide long-term neuro-protective strategies.
Sleep Architecture & Circadian Rest
Sleep Quality & Restorative Depth: Assesses genetic drivers of reported sleep quality and deep sleep quality to evaluate slow-wave sleep efficiency.
Neuro-Emotional Sleep Disruptions: Pinpoints susceptibility to mood-induced sleeplessness, clarifying how stress or emotional rumination disrupts sleep onset and continuity.
Neuro-Metabolic Cofactors & Cellular Energetics
Neurotransmitter Methylation: Evaluates MTHFR Activity to gauge folate conversion, crucial for neurotransmitter synthesis (serotonin, dopamine, norepinephrine) and homocysteinemia management.
MosaicDX offers patient-friendly sample collection kits that simplify testing. Our kits include visual, step-by-step instructions for test preparation and sample collection, personalized shipping cards, and pediatric collection bags if needed. With MosaicDX, patients can easily collect samples for testing with confidence and accuracy.
No, we do not. A genetic carrier refers to an individual who has inherited a recessive allele that has been shown to be responsible for an autosomal recessive disease or trait. A genetic carrier only has one recessive allele so while they do not show signs or symptoms of the trait or disease, they are able to pass along the recessive gene to their child. Our genetic testing is for screening purposes only to assess risk or predisposition for certain traits associated with health and wellness.
No. We do not use patient samples for further research or testing. We may use your de-identified and anonymized data to help improve our algorithm and reports. Your data will not be sold or shared to or with any 3rd parties/commercial interests.
Yes, we can delete the patient’s raw genetic sequence at any time. Please note that applicable federal and state laws require us to retain your patient report and the subset of your data that was used to generate that report for a specified period of time. We will be happy to delete any and all of your data that we are legally allowed to delete upon request. Please submit your request here.
We implement rigorous selection criteria when choosing which genes or SNPs to include in our panels. The selection and validation criteria are based upon peer-reviewed studies that show a significant association between the SNP variant and trait or condition, the magnitude of the odds ratio (OR) or hazard ratio (HR) to assess risk related to the variant, as well as the population or populations the gene and SNP variant were studied in, the population size, and replication of findings.
A genotype refers to the actual inherited genetic material of an individual that can influence or determine certain characteristics or traits. A phenotype is how the genotype is actually expressed, that is the observable or measurable characteristics or traits of an individual.
SNP is also called a Single Nucleotide Polymorphism. Your DNA consists of 4 main building blocks (nucleotides), Adenine (A), Thymine (T), Guanine (G), and Cytosine (C). In certain locations within your DNA, one person may have an A, whereas another may have a G. This difference in the base pair is often called a variant. This variant is an SNP.
In most situations, you do not have to resubmit a DNA buccal swab sample if you later want to order additional panels. The only time a new DNA buccal swab would need to be resubmitted is if the assay has had significant changes, or the patient previously requested that their DNA sequencing results be deleted.
Patients are sent a DNA Signature Collection Kit containing instructions, 1 cheek swab, a DNA Sample Envelope and a prepaid return envelope and biohazard zip-lock bag. Instructions can also be found on our website on the DNA Signature Profiles web page, along with an easy-to-follow video.
A person’s polygenic risk score is a statistical calculation based on the presence or absence of multiple genomic variants without taking environmental or other factors into account
Different states have regulations that define the scope of practice for practitioners. It is the practitioner’s responsibility to abide by these rules. Check with your state board of health to determine any restrictions related to laboratory testing. Please note, Mosaic Diagnostics does not offer testing in New York.
Once you have opened your account, you have the options of ordering kits to stock in your office or drop-ship kits directly to your patients through your MosaicDX portal.
Watch our short tutorial videos on how to conveniently
Walther DJ, Peter JU, Bashammakh S, et al. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science. 2003;299(5603):76-79. PMID 12649485.
Gao J, Pan Z, Jiao Z, et al. TPH2 gene polymorphisms and major depression: a meta-analysis. PLoS One. 2012;7(5):e36721. PMID 22693556.
Lemonde S, Turecki G, Bakish D, et al. Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J Neurosci. 2003;23(25):8788-99. PMID 12486195.
Savitz J and Drevets WC. Imaging phenomenology of major depressive disorder: towards a valid biomarker. Prog Neurobiol. 2009;88(1):17-31. PMID 19428809.
Du L, Bakish D, Lapierre YD, Ravindran AV, Hrdina PD. Association of polymorphism of serotonin 2A receptor gene with suicidal ideation in major depressive disorder. Am J Med Genet. 2000;96(1):56-60. PMID 10813604.
Zhao X, Sun L, Sun YH, et al. Association of HTR2A T102C and A-1438G polymorphisms with susceptibility to major depressive disorder: a meta-analysis. Neurol Sci. 2014;35(12):1857-66.
Egan MF, Kojima M, Callicott JH, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003;112(2):257-69.
Chen ZY, Patel PD, Sant G, et al. Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. J Neurosci. 2004;24(18):4401-11. PMID 15128854.
Binder EB, Salyakina D, Lichtner P, et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet. 2004;36(12):1319-25. PMID 15565110.
Zannas AS, Wiechmann T, Gassen NC, Binder EB. Gene-stress-epigenetic regulation of FKBP5: clinical and translational implications. Neuropsychopharmacology. 2016;41(1):261-74. PMID 26272048.
Bradley RG, Binder EB, Epstein MP, et al. Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene. Arch Gen Psychiatry. 2008;65(2):190-200.
Smoller JW, Yamaki LH, Fagerness JA, et al. The corticotropin-releasing hormone gene and behavioral inhibition in children at risk for panic disorder. Biol Psychiatry. 2005;57(12):1485-92.
DeRijk RH, de Kloet ER. Corticosteroid receptor polymorphisms: determinants of vulnerability and resilience. Eur J Pharmacol. 2008;583(2-3):303-11. PMID 18346725.
van Rossum EF, Feelders RA, van den Beld AW, et al. Association of the BclI variant in the glucocorticoid receptor gene with anthropometry and physiology in elderly men. Clin Endocrinol (Oxf). 2003;59(5):585-92. PMID 14616881.
Berridge CW, Waterhouse BD. The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res Brain Res Rev. 2003;42(1):33-84. PMID 12668290.
Dickel DE, Veenstra-VanderWeele J, Cox NJ, et al. Association of the neuronal glutamate transporter gene SLC1A1 with early-onset obsessive-compulsive disorder. Arch Gen Psychiatry. 2006;63(7):778-85. PMID 16818867.
Stewart SE, Yu D, Scharf JM, et al. Genome-wide association study of obsessive-compulsive disorder. Mol Psychiatry. 2013;18(7):788-98. PMID 22889921.
Rodrigues SM, Saslow LR, Garcia N, John OP, Keltner D, Gross JJ. Oxytocin receptor genetic variation relates to empathy and stress reactivity in humans. Proc Natl Acad Sci USA. 2009;106(50):21437-41. PMID 19934046.
Kim HS, Sherman DK, Sasaki JY, et al. Culture, distress, and oxytocin receptor polymorphism (OXTR) interact to influence emotional support seeking. Proc Natl Acad Sci USA. 2010;107(36):15717-21. PMID 20133858. decarboxylase (GAD67), is associated with childhood-onset schizophrenia and cortical gray matter volume loss. Mol Psychiatry. 2005;10(6):581-88. PMID 15505639.
Akbarian S, Huang HS. Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders. Brain Res Rev. 2006;52(2):293-304. PMID 16759706.
Egan MF, Goldberg TE, Kolachana BS, et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA. 2001;98(12):6917-22. PMID
Malhotra AK, Kestler LJ, Mazzanti C, Bates JA, Goldberg T, Goldman D. A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. Am J Psychiatry. 2002;159(4):652-54. PMID 11925305.
Barnett JH, Scoriels L, Munafo MR. Meta-analysis of the cognitive effects of the catechol-O-methyltransferase gene Val158/108Met polymorphism. Biol Psychiatry. 2008;64(2):137-44. PMID 18339359.
Pohjalainen T, Rinne JO, Nagren K, et al. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry. 1998;3(3):256-60. PMID
Noble EP. D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. Am J Med Genet B Neuropsychiatr Genet. 2003;116B(1):103-25. PMID 12497624.
Dubal DB, Yokoyama JS, Zhu L, et al. Life extension factor klotho enhances cognition. Cell Rep. 2014;7(4):1065-76. PMID 24813892. [KL-VS heterozygosity — general cognitive enhancement]
Belloy ME, Napolioni V, Han SS, et al. Association of Klotho-VS heterozygosity with risk of Alzheimer disease in individuals who carry APOE4. JAMA Neurol. 2020;77(7):849-62. PMID 32282020.
Kustanovich V, Merriman B, McGough J, et al. Biased paternal transmission of SNAP-25 risk alleles in attention-deficit hyperactivity disorder. Mol Psychiatry. 2003;8(3):309-15. PMID 12660803.
Li Z, Chang SH, Zhang LY, Gao L, Wang J. Molecular genetic studies of ADHD and its candidate genes: a review. Psychiatry Res. 2014;219(1):10-24. PMID 24863865.
Luo X, Kranzler HR, Zuo L, Wang S, Schork NJ, Gelernter J. CHRM2 gene predisposes to alcohol dependence, drug dependence, and affective disorders: results from an extended case-control structured association study. Hum Mol Genet. 2005;14(16):2421-32. PMID 16000316.
Dick DM, Aliev F, Kramer J, et al. Association of CHRM2 with IQ: converging evidence for a gene influencing intelligence. Behav Genet. 2007;37(2):265-72. PMID 17160701.
Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993;261(5123):921-23. PMID 8346443.
Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms, and therapy. Nat Rev Neurol. 2013;9(2):106-18. PMID 23296339.
Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA. 1993;90(5):1977-81. PMID 8446617.
Retey JV, Adam M, Honegger E, et al. A functional genetic variation of adenosine deaminase affects the duration and intensity of deep sleep in humans. Proc Natl Acad Sci USA. 2005;102(43):15676-81. PMID 16221767.
Lara DR, Dall’Igna OP, Ghisolfi ES, Brunstein MG. Involvement of adenosine in the neurobiology of schizophrenia and its therapeutic implications. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(4):617-29. PMID 16580767.
Rogaeva E, Meng Y, Lee JH, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet. 2007;39(2):168-77. PMID 17220890.
Reitz C, Mayeux R, Tang MX, et al. SORL1 variants and risk for late-onset Alzheimer disease. Arch Neurol. 2011;68(1):99-106. PMID 21220680.
Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet. 2013;45(12):1452-58. PMID 24162737.
Satake W, Nakabayashi Y, Mizuta I, et al. Genome-wide association study identifies common variants at four loci as risk factors for Parkinson’s disease. Nat Genet. 2009;41(12):1303-07. PMID
Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 2019;18(12):1091-102. PMID 31701892.
Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron. 2004;44(4):595-600. PMID 15530896.
Ross OA, Soto-Ortolaza AI, Heckman MG, et al. Association of LRRK2 exonic variants with susceptibility to Parkinson’s disease: a case-control study. Lancet Neurol. 2011;10(10):898-908.
Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N Engl J Med. 2009;361(17):1651-61. PMID 19846850.
Migdalska-Richards A, Schapira AH. The relationship between glucocerebrosidase mutations and Parkinson disease. J Neurochem. 2016;139 Suppl 1:77-90. PMID 26860875.
Jinn S, Drolet RE, Cramer PE, et al. TMEM175 deficiency impairs lysosomal and mitochondrial function and increases alpha-synuclein aggregation. Proc Natl Acad Sci USA. 2017;114(9):2389-94. PMID 28137859.
Nalls MA, Pankratz N, Lill CM, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. Nat Genet. 2014;46(9):989-93. PMID 25064009.
Dumitriu A, Pacheco CD, Wilk JB, et al. Cyclin-G-associated kinase modifies alpha-synuclein expression levels and toxicity in Parkinson’s disease: results from the GenePD Study. Hum Mol Genet. 2011;20(8):1478-87. PMID 21258085.
Katzenberg D, Young T, Finn L, et al. A CLOCK polymorphism associated with human diurnal preference. Sleep. 1998;21(6):569-76. PMID 9779516.
Serretti A, Benedetti F, Mandelli L, et al. Genetic dissection of psychopathological symptoms: insomnia in mood disorders and CLOCK gene polymorphism. Am J Med Genet B Neuropsychiatr Genet. 2003;121B(1):35-38. PMID 12898572.
Winkelmann J, Schormair B, Lichtner P, et al. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet. 2007;39(8):1000-06.
Stefansson H, Rye DB, Hicks A, et al. A genetic risk factor for periodic limb movements in sleep. N Engl J Med. 2007;357(7):639-47. PMID 17634447.
Kemlink D, Polo O, Frauscher B, et al. Replication of restless legs syndrome loci in three European populations. J Med Genet. 2009;46(5):315-18. PMID 19279021.
Schormair B, Kemlink D, Roeske D, et al. PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nat Genet. 2008;40(8):946-48. PMID 18660810.
Stein MB, Schork NJ, Gelernter J. A polymorphism of the beta1-adrenergic receptor is associated with low extraversion. Biol Psychiatry. 2004;56(4):217-24. PMID 15312808.
Gerstner JR, Vanderheyden WM, LaVaute T, et al. Time of day regulates subcellular trafficking, tripartite synaptic localization, and polyadenylation of the astrocytic Fabp7 mRNA. J Neurosci. 2012;32(5):1383-94. PMID 22279223. [FABP7 — astrocytic expression and sleep regulation]
Innis SM. Dietary omega 3 fatty acids and the developing brain. Brain Res. 2008;1237:35-43. PMID
Smith AD, Smith SM, de Jager CA, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One. 2010;5(9):e12244. PMID 20838622.
Sachdev PS. Homocysteine and brain atrophy. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(7):1152-61. PMID 16102882.
Blom HJ, Smulders Y. Overview of homocysteine and folate metabolism, with special references to cardiovascular disease and neural tube defects. J Inherit Metab Dis. 2011;34(1):75-81. PMID
Ross D, Siegel D. Functions of NQO1 in cellular protection and CoQ10 metabolism and its potential role as a redox sensitive molecular switch. Front Physiol. 2017;8:595. PMID 28883796.
Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta. 1995;1271(1):195-204. PMID 7599208.
Davis HR Jr, Zhu LJ, Hoos LM, et al. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem. 2004;279(32):33586-92. PMID 15173171.
Garcia-Calvo M, Lisnock J, Bull HG, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci USA. 2005;102(23):8132-37. PMID 15928087.
Pullinger CR, Eng C, Salen G, et al. Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J Clin Invest. 2002;110(1):109-17. PMID 12093894. [CYP7A1 — bile acid synthesis and cholesterol metabolism]
Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ. A promoter polymorphism in cholesterol 7alpha-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin. Atherosclerosis. 2005;180(2):407-15. PMID 15910869.
